PE20231099A1 - COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE Sppl2a - Google Patents
COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE Sppl2aInfo
- Publication number
- PE20231099A1 PE20231099A1 PE2023001167A PE2023001167A PE20231099A1 PE 20231099 A1 PE20231099 A1 PE 20231099A1 PE 2023001167 A PE2023001167 A PE 2023001167A PE 2023001167 A PE2023001167 A PE 2023001167A PE 20231099 A1 PE20231099 A1 PE 20231099A1
- Authority
- PE
- Peru
- Prior art keywords
- nhc
- sppl2a
- compounds
- c6alkyl
- oxo
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 abstract 1
- 101100516554 Caenorhabditis elegans nhr-5 gene Proteins 0.000 abstract 1
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract 1
- 102100029083 Minor histocompatibility antigen H13 Human genes 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 208000024340 acute graft versus host disease Diseases 0.000 abstract 1
- 125000005037 alkyl phenyl group Chemical group 0.000 abstract 1
- 208000017760 chronic graft versus host disease Diseases 0.000 abstract 1
- DHZYXWMZLAKTQV-UHFFFAOYSA-N diazepin-3-one Chemical group O=C1C=CC=CN=N1 DHZYXWMZLAKTQV-UHFFFAOYSA-N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000024908 graft versus host disease Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 235000019419 proteases Nutrition 0.000 abstract 1
- 108010031009 signal peptide peptidase Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063079604P | 2020-09-17 | 2020-09-17 | |
| PCT/IB2021/058398 WO2022058902A1 (en) | 2020-09-17 | 2021-09-15 | Compounds and compositions as sppl2a inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231099A1 true PE20231099A1 (es) | 2023-07-18 |
Family
ID=77897680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023001167A PE20231099A1 (es) | 2020-09-17 | 2021-09-15 | COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE Sppl2a |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US20230365571A1 (https=) |
| EP (2) | EP4578451A3 (https=) |
| JP (2) | JP7771172B2 (https=) |
| KR (1) | KR20230069947A (https=) |
| AU (1) | AU2021342783A1 (https=) |
| CA (1) | CA3192763A1 (https=) |
| CL (2) | CL2023000728A1 (https=) |
| CO (1) | CO2023004646A2 (https=) |
| CR (1) | CR20230142A (https=) |
| DK (1) | DK4214210T3 (https=) |
| DO (1) | DOP2023000055A (https=) |
| EC (1) | ECSP23027092A (https=) |
| ES (1) | ES3028668T3 (https=) |
| FI (1) | FI4214210T3 (https=) |
| GE (2) | GEAP202516217A (https=) |
| HR (1) | HRP20250562T1 (https=) |
| HU (1) | HUE071569T2 (https=) |
| IL (1) | IL300953B1 (https=) |
| JO (1) | JOP20230044A1 (https=) |
| LT (1) | LT4214210T (https=) |
| MA (1) | MA61557B1 (https=) |
| MD (1) | MD4214210T2 (https=) |
| MX (1) | MX2023003122A (https=) |
| PE (1) | PE20231099A1 (https=) |
| PL (1) | PL4214210T3 (https=) |
| PT (1) | PT4214210T (https=) |
| RS (1) | RS66874B1 (https=) |
| SI (1) | SI4214210T1 (https=) |
| SM (1) | SMT202500216T1 (https=) |
| WO (1) | WO2022058902A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116947813A (zh) * | 2023-07-06 | 2023-10-27 | 绍兴贝斯美化工股份有限公司 | 一种3-氯-4-氨基-1-(3-吡啶基)-1h-吡唑的制备方法 |
| US20250263416A1 (en) | 2024-02-15 | 2025-08-21 | Incyte Corporation | SPPL2a INHIBITORS |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2124503C1 (ru) * | 1992-05-18 | 1999-01-10 | И.Р.Сквибб энд Санз, Инк. | Гетероциклические азотсодержащие производные карбоновой кислоты, способ их получения и фармацевтическая композиция |
| GB9612622D0 (en) | 1996-06-17 | 1996-08-21 | Zeneca Ltd | Chemical process |
| US6432944B1 (en) | 2000-07-06 | 2002-08-13 | Bristol-Myers Squibb Company | Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| EP1773348A4 (en) | 2004-07-12 | 2009-05-20 | Idun Pharmaceuticals Inc | TETRA PEPTIDE ANALOGS |
| JP2008545780A (ja) | 2005-06-08 | 2008-12-18 | ノバルティス アクチエンゲゼルシャフト | 有機化合物 |
| WO2015160772A1 (en) | 2014-04-15 | 2015-10-22 | Janssen Pharmaceutica Nv | Tetrahydro-benzoimidazolyl modulators of tgr5 |
-
2021
- 2021-09-15 MX MX2023003122A patent/MX2023003122A/es unknown
- 2021-09-15 ES ES21773886T patent/ES3028668T3/es active Active
- 2021-09-15 LT LTEPPCT/IB2021/058398T patent/LT4214210T/lt unknown
- 2021-09-15 GE GEAP202516217A patent/GEAP202516217A/en unknown
- 2021-09-15 PL PL21773886.3T patent/PL4214210T3/pl unknown
- 2021-09-15 CR CR20230142A patent/CR20230142A/es unknown
- 2021-09-15 MA MA61557A patent/MA61557B1/fr unknown
- 2021-09-15 HU HUE21773886A patent/HUE071569T2/hu unknown
- 2021-09-15 PT PT217738863T patent/PT4214210T/pt unknown
- 2021-09-15 RS RS20250568A patent/RS66874B1/sr unknown
- 2021-09-15 GE GEAP202116217A patent/GEP20257771B/en unknown
- 2021-09-15 US US18/044,455 patent/US20230365571A1/en active Pending
- 2021-09-15 KR KR1020237011546A patent/KR20230069947A/ko active Pending
- 2021-09-15 PE PE2023001167A patent/PE20231099A1/es unknown
- 2021-09-15 MD MDE20230725T patent/MD4214210T2/ro unknown
- 2021-09-15 FI FIEP21773886.3T patent/FI4214210T3/fi active
- 2021-09-15 EP EP25163259.2A patent/EP4578451A3/en active Pending
- 2021-09-15 JP JP2023517751A patent/JP7771172B2/ja active Active
- 2021-09-15 AU AU2021342783A patent/AU2021342783A1/en active Pending
- 2021-09-15 HR HRP20250562TT patent/HRP20250562T1/hr unknown
- 2021-09-15 IL IL300953A patent/IL300953B1/en unknown
- 2021-09-15 EP EP21773886.3A patent/EP4214210B1/en active Active
- 2021-09-15 SI SI202130298T patent/SI4214210T1/sl unknown
- 2021-09-15 DK DK21773886.3T patent/DK4214210T3/da active
- 2021-09-15 SM SM20250216T patent/SMT202500216T1/it unknown
- 2021-09-15 WO PCT/IB2021/058398 patent/WO2022058902A1/en not_active Ceased
- 2021-09-15 CA CA3192763A patent/CA3192763A1/en active Pending
-
2023
- 2023-02-27 JO JOJO/P/2023/0044A patent/JOP20230044A1/ar unknown
- 2023-03-14 CL CL2023000728A patent/CL2023000728A1/es unknown
- 2023-03-16 DO DO2023000055A patent/DOP2023000055A/es unknown
- 2023-04-14 EC ECSENADI202327092A patent/ECSP23027092A/es unknown
- 2023-04-14 CO CONC2023/0004646A patent/CO2023004646A2/es unknown
-
2024
- 2024-04-29 CL CL2024001312A patent/CL2024001312A1/es unknown
-
2025
- 2025-11-05 JP JP2025186205A patent/JP2026041723A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20220141A1 (es) | Inhibidores de la proteina tirosina fosfatasa | |
| RU2336275C2 (ru) | Пиримидопроизводные, характеризующиеся антипролиферативной активностью, и фармацевтическая композиция | |
| PE20221336A1 (es) | Compuestos triciclicos sustituidos | |
| RU2401658C2 (ru) | Гетероциклические ингибиторы аспартилпротеазы | |
| PE20231312A1 (es) | Derivados triciclicos de carboxamida como inhibidores de la prmt5 | |
| PE20241625A1 (es) | Combinaciones farmaceuticas de inhibidores de sos1 para tratar o prevenir cancer | |
| PE20181144A1 (es) | Derivados de heteroarilo como inhibidores de parp | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR073688A1 (es) | Agonistas de receptores cb2, derivados de oxazoles y/o triazoles, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor, enfermedades autoinmunes y alergicas, entre otras. | |
| PE20231099A1 (es) | COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE Sppl2a | |
| AR057769A1 (es) | Pirazolo pirimidinas como inhibidores de map quinasa p38, metodos para utilizarlos y composiciones farmaceuticas | |
| AR114070A1 (es) | Inhibidores de glicolato oxidasa para el tratamiento de una enfermedad | |
| MA50065B1 (fr) | Dérivés de composés de spiro[3h-indole-3,2´-pyrrolidine]-2(1h)-one et dérivés utilisés comme inhibiteurs de mdm2-p53 | |
| AR062125A1 (es) | Compuestos que modulan el receptor cb2 y su utilizacion como medicamentos | |
| JP2018522034A5 (https=) | ||
| AR048361A1 (es) | Derivados de tetrahidroquinolina y un procedimiento para preparar los mismos | |
| PE20010482A1 (es) | Derivados de 3-ureido-pirazol y procedimiento para su preparacion | |
| AR068730A1 (es) | Compuestos de diaril 1,2,4-oxadiazol,composiciones farmaceuticas que los contienen,proceso de preparacion y uso de los mismos como agentes inmunosupresores en el tratamiento de enfermedades autoinmunes y/o inflamatorias cronicas. | |
| AR042691A1 (es) | Agonistas inversos del receptor cb1 procedimientos de obtencion y composiciones farmaceuticas. | |
| PE20080538A1 (es) | Derivado heterociclico fusionado y su uso | |
| PE20091157A1 (es) | Derivados biciclicos para usar en el tratamiento de afecciones asociadas con el receptor de androgeno - 155 | |
| RU2011116160A (ru) | Производные пиридина, замещенные гетероциклическим кольцом и y-глутамиламиногруппой и содержащие их противогрибковые средства | |
| EA022420B1 (ru) | Гетероциклические ингибиторы глутаминилциклазы (qc, ec 2.3.2.5) | |
| RU2015143676A (ru) | Модулятолры ship1 и относящиеся к ним способы | |
| JP2020023504A (ja) | マラリアの治療のための化合物及び方法 |